As we have demonstrated that hematopoietic and blood cancers are dependent on Fbxo7 expression, future studies on Fbxo7-regulated metabolic pathways in T cell malignancies may reveal actionable vulnerabilities. This evidence concerns the gene FBXO7 and hematopoietic and lymphoid system neoplasm.